ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: PUB311

Pathophysiological Insights and Therapeutic Options for Cardiovascular Disease in CKD

Session Information

Category: Hypertension and CVD

  • 1601 Hypertension and CVD: Basic

Author

  • Jankowski, Joachim, Universitatsklinikum Aachen, Aachen, Germany
Background

Patients with chronic kidney disease (CKD) are at an increased risk of cardiovascular complications, including coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. The incidence and prevalence of cardiovascular events are already higher in patients with early CKD stages (CKD stages 1-3) compared to the general population, but the risk significantly escalates in patients with advanced CKD stages (CKD stages 4-5). In fact, cardiovascular disease surpasses end-stage kidney disease (CKD stage 5) as the leading cause of death in this high-risk population. CKD induces a chronic proinflammatory state throughout the body, leading to vascular and myocardial remodeling processes.

Methods

The information presented in this article is based on a comprehensive review of existing literature related to cardiovascular disease in patients with CKD. Relevant studies, research articles, and clinical data were collected from various databases and sources. The selected information focuses on the pathophysiology, clinical consequences, and underlying mechanisms of cardiovascular disease in CKD.

Results

Patients with CKD face an elevated risk of cardiovascular complications, with cardiovascular disease being the leading cause of mortality in this population. CKD contributes to a systemic proinflammatory state that drives vascular and myocardial remodeling processes. These processes give rise to atherosclerotic lesions, vascular calcification, vascular senescence, myocardial fibrosis, and cardiac valve calcification. The cardiovascular manifestations in CKD resemble an accelerated aging process, further exacerbating the cardiovascular risk.

Conclusion

The understanding of cardiovascular disease in CKD is crucial due to its high prevalence and impact on patient outcomes. The systemic proinflammatory state induced by CKD contributes to significant vascular and myocardial alterations, leading to various cardiovascular complications. Recognizing the accelerated aging effect on the cardiovascular system in CKD patients is essential for effective management and the development of preventive strategies. Further research is warranted to explore novel therapeutic approaches and interventions targeting cardiovascular disease in CKD.

Funding

  • Government Support – Non-U.S.